Osteoporosis
Conference Coverage
Osteoporosis drugs don’t worsen COVID-19 risk, may help
“What we observed is that there is no harm. Treatments should be continued.”
Conference Coverage
Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis
Denosumab “may be considered as an alternative first-line therapy in higher-risk patients and in those who are contraindicated for the oral...
Conference Coverage
Osteoporosis underdiagnosed in older men with fracture
Even men at high risk for the disease are overlooked for screening as osteoporosis has been thought of as a disease of White women.
Conference Coverage
Treatment sequence with romosozumab influences osteoporosis outcomes
Administering anabolic agents followed by antiresorptives is associated with higher gains in bone mineral density and improved bone-turnover...
From the Journals
Vertebral fractures in COVID-19 linked to mortality
Radiologic thoracic vertebral fractures were found in one-third of COVID-19 patients who underwent lateral chest x-rays, and those patients were...
Conference Coverage
Combine calculators and medications to manage risk in osteoporosis patients
Expert shares clinical pearls on diagnosis and treatment of osteoporosis in men and women.
Conference Coverage
Burosumab is a ‘game changer,’ effective in all subgroups of XLH
The recently approved treatment improved serum phosphorus and key measures of pain and stiffness in subgroups of adults with this rare form of...
From the Journals
Low DHT linked to hip fracture in men
In older men, circulating levels of the androgen dihydrotestosterone and sex hormone binding globulin independently predict risk of hip fracture,...
Conference Coverage
Reassuring rheumatic disease patients on value of bisphosphonates
Dr. Marcy B. Bolster addresses common patient concerns about bisphosphonate use.
Conference Coverage
Longer bisphosphonate use ups AFF risk, but not all is tied to drug
The clinical implications of research to date are that “the risk of AFF should not dissuade patients and providers from short-term use of...
Conference Coverage
Treat-to-target strategy ‘not ready for primetime’ in osteoporosis
Debaters at a session of the recent virtual ASBMR 2020 annual meeting could have gone either way on this topic, but data and evidence are...